[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transformed-indolent-b-cell-non-hodgkin-lymphoma-to-diffuse-large-b-cell-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transformed-indolent-b-cell-non-hodgkin-lymphoma-to-diffuse-large-b-cell-lymphoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,72,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100517310","phase-1-testing-the-combination-of-anti-cancer-drugs-mosunetuzumab-polatuzumab-vedotin-and-lenalidomide-for-the-treatment-of-relapsedrefractory-diffuse-large-b-cell-lymphoma-100517310",false,"NCT06015880","Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma","A Phase 1 Study of Mosunetuzumab With Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed\u002FRefractory (R\u002FR) Diffuse Large B-Cell Lymphoma (DLBCL)","Inclusion Criteria:\n\n* Patients must have histologically confirmed DLBCL NOS, high-grade B-cell lymphoma, or transformed indolent lymphoma as per the World Health Organization 2022 criteria\n* All patients will have relapsed\u002Frefractory DLBCL after 1 or more prior lines of therapy with the exception of patients receiving CAR T in second line that have a D score of 3 at day (D)+ 30 through D+ 90\n* Patients who progressed\u002Frelapsed after prior polatuzumab vedotin are allowed\n* For the expansion cohorts only: cohort A must have Deauville score of ≥ 3 with the first 90 days) after standard of care chimeric antigen receptor (CAR) T-cell therapy; cohort B- other patients with relapsed\u002Frefractory after 1 or more prior lines of therapy (e.g. relapse after Day 90 from CAR-T, or relapsed after other therapies and were not considered candidates for CAR-T)\n* All patients that have failed 1 line of therapy will be eligible with the exception of a 12 patient cohort (A) that will require prior CAR T therapy\n* Measurable disease by CT or PET scan, with one or more sites of disease \\>= 1.5 cm in longest dimension\n* Age \\>= 18 years\n\n  * Because no dosing or adverse event data are currently available on the use of mosunetuzumab in combination with polatuzumab vedotin, and lenalidomide in patients \\\u003C 18 years of age, children are excluded from this study\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2 (Karnofsky \\>= 60%)\n* Life expectancy \\>= 12 weeks\n* Absolute neutrophil count \\>= 1,000\u002FmcL\n* Platelets \\>= 50,000\u002FmcL without transfusion for 2 weeks prior to cycle 1 day 1 (C1D1)\n* Hemoglobin \\>= 9 g\u002FdL\n* Total bilirubin =\\\u003C 1.5 × institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =\\\u003C 3 × ULN may be enrolled)\n* Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002F alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase \\[SGPT\\]) =\\\u003C 3 × ULN (AST and\u002For ALT =\\\u003C 5 × ULN for patients with liver involvement)\n* Alkaline phosphatase =\\\u003C 2.5 × ULN (=\\\u003C 5 × ULN for patients with documented liver involvement or bone metastases)\n* Creatinine clearance \\>= 30 mL\u002Fmin\u002F1.73 m\\^2 by Cockcroft-Gault: (140- age) × (weight in kg) × (0.85 if female) 72 × (serum creatinine in mg\u002FdL)\n* International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =\\\u003C 1.5 × ULN (This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose.)\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n\n  * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients with treated brain metastases are eligible if follow-up brain imaging 6-8 weeks after central nervous system (CNS)-directed therapy shows no evidence of progression or CNS lymphoma\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs, as defined below:\n\n  * Women must remain abstinent or use contraceptive methods with a failure rate of 1% per year during the treatment period and for 3 months after the final dose of mosunetuzumab, 3 months after the final dose of polatuzumab vedotin, and 1 month after the last dose of lenalidomide\n  * For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:\n  * With female partners of childbearing potential, men must remain abstinent or use a condom during the treatment period, 5 months after the final dose of polatuzumab vedotin, and 1 month after the last dose of lenalidomide\n* Some concurrent cancer therapeutics (e.g., prostate, breast hormonal-based therapy) are allowed\n* Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants\n* Agree to comply with all local requirements of the lenalidomide risk minimization plan\n\nExclusion Criteria:\n\n* Plasmablastic lymphoma, primary mediastinal B-cell lymphoma, gray zone lymphoma\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> grade 1) with the exception of alopecia\n* Patients who are receiving any other investigational agents or treatments\n* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he\u002Fshe were to participate in the study or confounds the ability to interpret data from the study\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to mosunetuzumab or other agents used in study\n* Patients with uncontrolled intercurrent illness\n* Uncontrolled or known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (defined as ongoing signs\u002Fsymptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and\u002For other treatment) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to first study treatment administration\n* Active CNS involvement or detectable disease by lymphoma, including leptomeningeal involvement\n* Pregnant women are excluded from this study because mosunetuzumab is bispecific antibody with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with mosunetuzumab, breastfeeding should be discontinued if the mother is treated with mosunetuzumab. These potential risks may also apply to other agents used in this study. Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of mosunetuzumab, 3 months after the final dose of polatuzumab vedotin, and 1 month after the final dose of lenalidomide\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2 or better\n* Known or suspected chronic active Epstein-Barr virus (EBV) infection\n* Patients with any other significant condition(s) that would make this protocol unreasonably hazardous\n\n  * Current \\> grade 1 peripheral neuropathy\n  * Prior solid organ transplantation\n  * Patients with known or suspected history of hemophagocytic lymphohistiocytosis (HLH)\n  * Patients with history of confirmed progressive multifocal leukoencephalopathy (PML)\n  * Currently active or uncontrolled autoimmune disease\n\n    * Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\n    * Patients with controlled type 1 diabetes mellitus who are on an insulin regimen are eligible for the study\n    * Patients with a history of disease-related immune thrombocytopenic purpura, autoimmune hemolytic anemia, or other stable autoimmune diseases may be eligible","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mosunetuzumab and polatuzumab vedotin are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Polatuzumab, linked to a toxic agent called vedotin, attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Lenalidomide may stimulate or suppress the immune system in different ways and stop cancer cells from growing and by preventing the growth of new blood vessels that cancer cells need to grow. Giving mosunetuzumab with polatuzumab vedotin and lenalidomide may work better in treating patients with relapsed\u002Frefractory DLBCL.",[26,27,28],"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","RECRUITING","2026-06-16",{"date":32,"type":33},"2026-06-17","ACTUAL",{"date":35,"type":33},"2024-05-20",{"date":37,"type":20},"2027-06-30",{"name":39,"class":40},"National Cancer Institute (NCI)","NIH",8,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100642651","phase-1-axatilimab--car-t-for-high-risk-lymphoma-100642651","NCT07638982","Axatilimab + CAR-T for High-Risk Lymphoma","An Open-label, Phase I Trial, With an Expansion Cohort: Macrophage Conditioning to Synergize With CAR-T in High-risk Lymphoma (MAC-SHIFT)","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed large B-cell lymphoma\n* Presence of one or more high-risk features\n* Eligible to receive CAR-T according to the FDA label\n* Measurable disease by CT or PET\n* Adequate organ function unless related to lymphoma involvement:\n* Pulse oximetry ≥ 92% on room air\n* Ejection Fraction ≥ 40%\n* ALT\u002FAST \\\u003C 5x ULN\n* Bilirubin \\\u003C 3 x ULN\n* Calculated or measured creatinine Clearance ≥ 30 mL\u002Fmin\n\nExclusion Criteria:\n\n* KPS \\\u003C60\n* Second malignancy with a high metastatic potential within 3 years\n* Active CNS involvement. Treated CNS disease is allowed\n* Active HBV or HCV infection.\n* Active uncontrolled infections\n* Known HIV positive status\n* Allogeneic transplant within 100 days of enrollment\n* Active acute or chronic graft versus host disease\n* History of acute or chronic pancreatitis\n* History of myositis","8 Years",{"count":51,"type":20},29,[23],"Axatilimab + CAR-T in High-Risk Lymphoma",[55,28,56,57,58,59],"Diffuse Large B Cell Lymphoma (DLBCL)","High-grade B-cell Lymphoma (HGBCL)","High-Grade B-Cell Lymphoma, Nos","PMBCL","Follicular Grade 3 Lymphoma","NOT_YET_RECRUITING","2026-06-05",{"date":63,"type":33},"2026-06-10",{"date":65,"type":20},"2026-10-31",{"date":67,"type":20},"2029-12-31",{"name":69,"class":70},"Northside Hospital, Inc.","OTHER",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":71},"100497272","phase-1-tegavivint-for-treating-patients-with-relapsed-or-refractory-large-b-cell-lymphoma-100497272","NCT05755087","Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma","Phase Ib Trial of Tegavivint in Patients With Relapsed\u002FRefractory C-MYC Overexpressing Large B-Cell Lymphoma","Inclusion Criteria:\n\nOne of the following three conditions:\n\n* Relapsed\u002Frefractory histologically confirmed germinal center B-cell-like (GCB) and non-GCB diffuse large B cell lymphoma (DLBCL) with the following features:\n\n  * Increased expression of MYC (\\>= 40%) and BCL2 (\\>= 50%) by immunohistochemistry (IHC) or\n  * Presence of isolated MYC translocation Or\n* Relapsed\u002Frefractory histologically confirmed high-grade B-cell lymphoma (HGBCL) (double hit \\[DH\\] and triple hit \\[TH\\]) with translocations of MYC and BCL2 and\u002For BCL6 Or\n* Histologic transformation of indolent non-Hodgkin's lymphoma (NHL) to DLBCL\n\n  * Presence of BCL2 translocation with increased expression of MYC (≥40%) with or without MYC translocation\n* Patients must have had at least two prior systemic therapies\n* Patients must be ineligible for or refused autologous or allogenic hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy. Prior autologous stem cell transplant and\u002For CAR-T are allowed, if received \\>= 3 months prior to enrollment\n* Age \\>= 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Patients must have radiographically measurable disease by standard positron emission tomography (PET) uptake with at least one site of measured disease by standardized uptake value (SUV)\n* Absolute neutrophil count (ANC) ≥ 500\u002FmcL\n* Platelet count ≥ 25,000\u002FmcL\n* Total bilirubin =\\\u003C 1.5 x the upper limit of the normal range (ULN)\n* Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) \\\u003C 3 x institutional ULN\n* Creatinine clearance \\>= 60 ml\u002Fmin by Cockcroft-Gault (actual body weight will be used to estimate creatinine clearance)\n* Patients must be willing and able to understand and give written informed consent and comply with all study related procedures\n* Women of child-bearing potential (WOCBP) and men who are sexually active with WOCBP must agree to use one hormonal contraceptive (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy or tubal ligation; and one effective method of contraception, including male condom, female condom, cervical cap, diaphragm or contraceptive sponge or abstain from sex for the duration of study participation and for 4 months following completion of tegavivint administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n\nContraception includes:\n\n* Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\n* Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment\n* Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patient\n* Use of oral (estrogen and progesterone), injected or implanted combined hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate \\\u003C1%), for example hormone vaginal ring or transdermal hormone contraception\n* Sexually active males must use a condom during intercourse while taking drug and for 4 months after stopping study treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential\n\nExclusion Criteria:\n\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to tegavivint or other agents used in study\n* Known active central nervous system (CNS) lymphoma, history of CNS involvement allowed if in remission for \\>= 3 months\n* Evidence of chronic active Hepatitis B, chronic active Hepatitis C infection\n* Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy (e.g., strong CYP3A inhibitors and\u002For concomitant medications that are excluded) are ineligible because of the potential for pharmacokinetic interactions with tegavivint\n* Known history of active TB (Bacillus Tuberculosis)\n* Major surgery within 3 weeks prior to start of study treatment\n* Clinically significant, uncontrolled heart disease and\u002For cardiac repolarization abnormality or corrected QT interval (QTc) \\> 480 msec\n* Uncontrolled concurrent illness including, but not limited to: ongoing or active infection (Viral, bacterial, fungal or other)\n* Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnant and breastfeeding women are excluded from this study. The effects of tegavivint on the developing human fetus have the potential for teratogenic or abortifacient effects. There is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with tegavivint\n* Patients with abnormal serum chemistry values other than the specific limits detailed above, that in the opinion of the investigator is considered to be clinically significant, should be discussed with the Study PI before being enrolled in the study\n* Personal history of malignancy except:\n\n  * Cervical intraepithelial neoplasia;\n  * Skin basal cell carcinoma;\n  * Treated localized prostate carcinoma with prostate specific antigen (PSA) \\\u003C1 ng\u002FmL or untreated indolent prostate cancer\n  * Neoplasia treated with curative intent, in remission for at least three years and considered at low risk of relapse",{"count":80,"type":20},18,[23],"This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint may help control the disease.",[84,85,86,87,88,89,90,91,28],"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","2026-02-24",{"date":94,"type":33},"2026-02-27",{"date":96,"type":33},"2023-03-06",{"date":98,"type":20},"2028-03-05",{"name":100,"class":70},"Lapo Alinari",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100534424","phase-2-epcoritamab-compared-to-observation-for-treating-b-cell-lymphoma-patients-not-in-complete-remission-after-cd19-directed-car-t-therapy-100534424","NCT06238648","Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy","Multicenter, Randomized Phase II Study of Epcoritamab for Patients With Aggressive B-Cell Lymphomas Achieving a Partial Response After CD19-Directed CAR-T Therapy","Inclusion Criteria:\n\n* Men and women \\>= 18 years of age\n* Documented histological confirmation of diffuse large b-cell lymphoma not otherwise specified \\[DLBCL NOS\\], primary mediastinal large b-cell lymphoma (LBCL), or transformations of indolent B-cell lymphomas, according to the 5th edition of World Health Organization (WHO) classification of lymphoid neoplasms, with CD20 positivity as determined by assessment of tumor cells =\\\u003C 6 months prior to registration pre- CAR-T biopsy specimen by immunohistochemistry or flow cytometry\n* Patients treated with the commercially available CD19-directed CAR-T products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), or lisocabtagene maraleucel (liso-cel), and who have a partial response at day 30 +\u002F- 7 days PET- CT assessment based on Lugano criteria (Deauville score of 4 or 5)\n* Documented measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2. (Form is available on the Academic and Community Cancer Research United \\[ACCRU\\] web site under Study Resources -\\> Forms)\n* Absolute neutrophil count (ANC) \\>= 1,000\u002Fmm\\^3, granulocyte colony stimulating factor (G-CSF) allowed (obtained =\\\u003C 14 days prior to registration)\n* Platelet count \\>= 50,000\u002Fmm\\^3 (obtained =\\\u003C 14 days prior to registration)\n* Hemoglobin \\>= 7.0 g\u002FdL if asymptomatic or hemoglobin \\> 8 if symptomatic; transfusion support allowed, if necessary (obtained =\\\u003C 14 days prior to registration)\n\n  * NOTE: symptoms include shortness of breath, fatigue, lightheadedness\n* Total bilirubin =\\\u003C 1.5 x upper limit of normal (ULN) unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin or lymphoma involvement of the liver and total bilirubin is =\\\u003C 5 x ULN (obtained =\\\u003C 14 days prior to registration)\n* Alanine aminotransferase (ALT) and aspartate transaminase (AST) =\\\u003C 3 x ULN (=\\\u003C 5 x ULN for patients with liver involvement) (obtained =\\\u003C 14 days prior to registration)\n* Calculated creatinine clearance must be \\>= 45 mL\u002Fmin using the Crockcroft- Gault formula (obtained =\\\u003C 14 days prior to registration)\n\n  * NOTE: If your site laboratory reports use different units of measurement than what is required by the protocol eligibility requirements, please use the \"Lab Test Unit Conversion Worksheet\" available on the ACCRU website under \"General Forms.\"\n* Negative serum pregnancy test done =\\\u003C 7 days prior to registration for a woman of childbearing potential (WOCBP) only\n\n  * NOTE: A WOCBP is a sexually mature female who:\n\n    * Has not undergone a hysterectomy or bilateral oophorectomy; or\n    * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)\n* Provide informed written consent =\\\u003C 28 days prior to registration\n* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study, i.e., active treatment and clinical follow-up)\n* Willing to provide mandatory tissue specimens and blood specimens for correlative research purposes\n\nExclusion Criteria:\n\n* Patients post CAR-T who have bulky disease defined as a disease focus \\>= 7.5cm in diameter at day 30 +\u002F- 7 days PET-CT assessment\n* Patients post CAR-T who have progressive disease, stable disease or complete response at day 30 +\u002F- 7 days PET-CT assessment based on Lugano criteria\n* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effect on the developing fetus and newborn are unknown\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential who are unwilling to employ adequate contraception (men and women)\n* Any of the following prior therapies:\n\n  * CD20xCD3 bispecific antibody at any point prior to registration\n  * CD20-targeted monoclonal antibody (e.g., rituximab, obinutuzumab or biosimilars) =\\\u003C 4 weeks prior to registration\n* Ongoing cytokine release syndrome (CRS) or neurotoxicity post CAR-T\n* Prior grade 4 CRS or neurotoxicity after most recently administered CAR-T\n* Primary central nervous system (CNS) lymphoma or CNS involvement by lymphoma at screening and based on clinical symptoms, MRI, or lumbar puncture\n* Co-morbid systemic illness or other severe concurrent disease which, in the judgement of the investigator, would make the patient inappropriate for entry into the study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Uncontrolled intercurrent illness including, but not limited to:\n\n  * Ongoing or active infection requiring systemic treatment (excluding prophylactic treatment) =\\\u003C 14 days prior to registration, including COVID- 19 infection.\n\n    * NOTE: If evidence of chronic hepatitis B virus (HBV) infection, HBV viral load must be undetectable and on suppressive therapy.\n    * NOTE: If history of treated hepatitis C virus (HCV) infection, HCV viral load must be undetectable.\n    * NOTE: Patients known to be human immunodeficiency virus (HIV) positive, but stable on anti-retroviral therapy with an undetectable HIV viral load pre-CART, are eligible for this trial.\n    * NOTE: Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment\n    * NOTE: Past COVID-19 infection may be a risk factor, but if resolved symptoms and the subject is vaccinated, they may be enrolled\n  * Symptomatic congestive heart failure (New York Heart Association \\[NYHA\\] class 3 or 4)\n  * Unstable angina pectoris\n  * Unstable cardiac arrhythmia present =\\\u003C 14 days prior to registration\n  * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirement\n  * History or presence of CNS disorder such as seizure disorder (not including resolved childhood febrile seizures), cerebrovascular ischemia\u002Fhemorrhage (not including transient ischemic attacks), cerebellar disease, or any autoimmune disease with CNS involvement\n* Receiving any other investigational agent which would be considered treatment for the primary neoplasm =\\\u003C 14 days prior to registration\n* Other active malignancy requiring therapy \\\u003C 2 years prior to registration (localized non-melanoma skin cancer is allowed)\n* Clinically significant cardiovascular disease, including: Myocardial infarction within 1 year prior to randomization, or unstable or uncontrolled disease\u002Fcondition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association class III-IV) cardiac arrhythmia (Common Terminology Criteria for Adverse Events \\[CTCAE\\] version 5.0 grade 2 or higher), or clinically significant electrocardiogram (ECG) abnormalities",{"count":109,"type":20},120,[111],"PHASE2","This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Epcoritamab is a bispecific antibody. It works by simultaneously attaching to a molecule called CD20 on cancerous B-cells and a molecule called CD3 on effector T-cells, which are a type of immune cell. When epcoritamab binds to CD20 and CD3, it brings the two cells together and activates the T-cells to kill the cancerous B-cells. Epcoritamab may increase a patient's chances of achieving complete remission after CD19-directed CAR-T therapy, compared to standard observation.",[26,114,28],"Primary Mediastinal Large B-Cell Lymphoma","2024-09-24",{"date":117,"type":33},"2024-09-26",{"date":119,"type":33},"2024-01-31",{"date":121,"type":20},"2030-12-31",{"name":123,"class":70},"Academic and Community Cancer Research United",6]